homefeedbacksupportlog on 4-Jul-2008 
  About F1000

 What is F1000 Biology?
 Key features
 How it's organized
 FAQs
 Faculties and sections
 Scope of sections
 List of Faculty Members
 The evaluation system
 Citing F1000
 Take a tour of the site
 Accessing fulltexts
 PubMed linkout
 How to subscribe
 Academic subscriptions
 Corporate subscriptions
 Try F1000 for free
 Who we are
 Media information
 Librarian resources
 Press releases
 In the press
 Developing countries
 F1000 Medicine
 Terms and conditions
 Privacy policy
 Contact us


Jonathan Schapiro
AIDS Service, National Hemophilia Center, Tal-Hashomer, Israel

Faculty Member: PHARMACOLOGY & DRUG DISCOVERY > Antimicrobial agents [ since 30 August 2006 ]
[ Evaluations ]
to email [Help]
Evaluations

HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.
Descamps D, Assoumou L, …, Costagliola D, on behalf of the ANRS AC-11 Resistance Study Group
J Antimicrob Chemother 2008 Jun 13 [abstract on PubMed] [related articles] [full text]
Selected by | Jonathan Schapiro
Evaluated 26 Jun 2008

High-resolution structure of unbound human immunodeficiency virus 1 subtype C protease: implications of flap dynamics and drug resistance.
Coman RM, Robbins AH, …, Dunn BM, McKenna R
Acta Crystallogr D Biol Crystallogr 2008 Jul 64(Pt 7):754-63 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Jonathan Schapiro
Evaluated 26 Jun 2008

Stavudine plasma concentrations and lipoatrophy.
Ter Hofstede HJ, Koopmans PP, Burger DM
J Antimicrob Chemother 2008 Feb 14 [abstract on PubMed] [related articles] [full text]
Selected by | Jonathan Schapiro
Evaluated 26 Feb 2008

Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
Chi BH, Sinkala M, …, Safrit JT, Stringer JS
Lancet 2007 Nov 17 370(9600):1698-705 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Jonathan Schapiro
Evaluated 23 Nov 2007

A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients.
Best BM, Goicoechea M, …, Haubrich RH, California Collaborative Treatment Group 578 Study Team
J Acquir Immune Defic Syndr 2007 Dec 1 46(4):433-42 [abstract on PubMed] [related articles] [order article]
Selected by | Jonathan Schapiro
Evaluated 24 Sep 2007

Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
Song R, Jelagat J, …, Shikely K, Essajee S
Pediatrics 2007 Oct 120(4):e856-61 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Jonathan Schapiro
Evaluated 24 Sep 2007

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Madruga JV, Berger D, …, Spinosa-Guzman S, TITAN study group
Lancet 2007 Jul 7 370(9581):49-58 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Jonathan Schapiro
Evaluated 23 Jul 2007

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Madruga JV, Cahn P, …, Woodfall B, DUET-1 study group
Lancet 2007 Jul 7 370(9581):29-38 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Jonathan Schapiro
Evaluated 23 Jul 2007

Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system.
Fukushima K, Terasaka S, …, Sugioka N, Takada K
Biol Pharm Bull 2007 Apr 30(4):733-8 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Jonathan Schapiro
Evaluated 6 Jun 2007

A virological benefit from an induction/maintenance strategy: the Forte trial.
Asboe D, Williams IG, …, Babiker AG, Forte Steering Committee
Antivir Ther 2007 12(1):47-54 [abstract on PubMed] [related articles] [order article]
Selected by | Jonathan Schapiro
Evaluated 22 May 2007

Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.
Seyler C, Adjé-Touré C, …, Toure S, Anglaret X
AIDS 2007 May 31 21(9):1157-64 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Jonathan Schapiro
Evaluated 22 May 2007

Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.
Viani RM, Peralta L, …, Wilson CM, Adolescent Medicine Trials Network for HIV/AIDS Interventions
J Infect Dis 2006 Dec 1 194(11):1505-9 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Jonathan Schapiro
Evaluated 14 Nov 2006

Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag.
Zhou J, Chen CH, Aiken C
J Virol 2006 Dec 80(24):12095-101 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Jonathan Schapiro
Evaluated 19 Oct 2006

In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).
Adamson CS, Ablan SD, …, Wild CT, Freed EO
J Virol 2006 Nov 80(22):10957-71 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Jonathan Schapiro
Evaluated 22 Sep 2006

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients.
DeJesus E, Berger D, …, Kearney BP, for the 183-0101 Study Team
J Acquir Immune Defic Syndr 2006 Sep 43(1):1-5 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Jonathan Schapiro
Evaluated 21 Sep 2006

Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor.
Ford SL, Reddy YS, …, Stein DS, Johnson MA
Antimicrob Agents Chemother 2006 Jun 50(6):2201-6 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Jonathan Schapiro
Evaluated 20 Sep 2006

^Top  Back to Faculty Members


© 1999-2008 Biology Reports Ltd unless otherwise stated < info@f1000.com >   Terms and conditions   Legal info